Randomized double-blinded pilot clinical study of the antidiabetic activity of balanites aegyptiaca and uplc-esi-ms/ms identification of its metabolites

Pharmaceutical Biology

Volumn 55, Issue 1, 2017, Pages 1954-1961

  Rashad, Hend ^a   Metwally, Fateheya M ^a   Ezzat, Shahira M ^b   Salama, Maha M ^b   Hasheesh, Adel ^a   Motaal, Amira Abdel ^b  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Antidiabetic activity; Balanites aegyptiaca; Clinical study; UPLC profiling

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIHYPERTENSIVE AGENT; ASPARTATE AMINOTRANSFERASE; BALANITES AEGYPTIACA EXTRACT; C PEPTIDE; CHOLESTEROL; CREATININE; GELATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; PHENOL DERIVATIVE; PLACEBO; SAPONIN; STEROL GLUCOSIDE; SULFONYLUREA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA; ANTIDIABETIC AGENT; PLANT EXTRACT;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIDIABETIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; EGYPTIAN; ELECTROSPRAY MASS SPECTROMETRY; FASTING; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; HUMAN; INSULIN BLOOD LEVEL; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL; MALE; METABOLIC PARAMETERS; METABOLITE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL SUPPORT; PERICARP; PILOT STUDY; POSTPRANDIAL STATE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UREA BLOOD LEVEL; BALANITES; BLOOD; DRUG EFFECTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MIDDLE AGED; PROCEDURES; TANDEM MASS SPECTROMETRY;

BALANITES; BLOOD GLUCOSE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PILOT PROJECTS; PLANT EXTRACTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 85044929033     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.1080/13880209.2017.1354388     Document Type: Article

References (27)

1. Abdel Motaal A, El-Askary H, Crockett S, Kunert O, Sakr B, Shaker S, Grigore A, Albulescu R, Bauer R. 2015. Aldose reductase inhibition of a saponin-rich fraction and new furostanol saponin derivatives from Balanites aegyptiaca. Phytomedicine. 22:829–836.
2. Abdel Motaal A, Shaker S, Haddad PS. 2012. Antidiabetic activity of standardized extracts of Balanites aegyptiaca fruits using cell-based bioassays. Phcog J. 4:20–24.
3. Campbell-Tofte J, Hansen HS, Mu H, Molgaard P. 2007. Increased lipids in non-lipogenic tissues are indicators of the severity of type 2 diabetes in mice. Prostaglandins Leukot Essent Fatty Acids. 76:9–18.
4. Chapagain BP, Wiesman Z. 2008. Metabolite profiling of saponins in Balanites aegyptiaca plant tissues using LC (RI)-ESI/MS and MALDI-TOF/ MS. Metabolomics. 4:357–366.
5. Cui M, Song F, Zhou Y, Liu Z, Liu S. 2000. Rapid identification of saponins in plant extracts by electrospray ionization multi-stage tandem mass spectrometry and liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 14:1280–1286.
6. Deshpande AD, Harris-Hayes M, Schootman M. 2008. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 88: 1254–1264.
7. Duvillard L, Pont F, Florentin E, Gambert P, Verges B. 2000. Inefficiency of insulin therapy to correct apolipoprotein A-I metabolic abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis. 152:229–237.
8. Farag MA, Porzel A, Wessjohann LA. 2015. Unraveling the active hypoglycemic agent trigonelline in Balanites aegyptiaca date fruit using metabolite fingerprinting by NMR. J Pharm Biomed Anal. 10:383–387.
9. Gad MZ, El-Sawalhi MM, Ismail MF, El-Tanbouly ND. 2006. Biochemical study of the anti-diabetic action of the Egyptian plants fenugreek and balanites. Mol Cell Biochem. 281:173–183.
10. Gertsch J. 2009. How scientific is the science in ethnopharmacology? Historical perspectives and epistemological problems. J Ethnopharmacol. 122:177–183.
11. Hall JBWD. 1991. Balanites aegyptiaca Del.-A Monograph, School of Agricultural and Forest Science.: University of Wales, Banger.
12. Kamel MS. 1998. A furostanol saponin from fruits of Balanites aegyptiaca. Phytochemistry. 48:755–757.
13. Kamel MS, Ohtani K, Kurokawa T, Assaf MH, el-Shanawany MA, Ali AA, Kasai R, Ishibashi S, Tanaka O. 1991. Studies on Balanites aegyptiaca fruits, an antidiabetic Egyptian folk medicine. Chem Pharm Bull. 39:1229–1233.
14. Koski RR. 2006. Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus. Diabetes Educ. 32:869–876.
15. Liang F, Li LJ, Abliz Z, Yang YC, Shi JG. 2002. Structural characterization of steroidal saponins by electrospray ionization and fast-atom bombardment tandem mass spectrometry. Rapid Commun Mass Spectrom. 16: 1168–1173.
16. Liu Y, Liang F, Cui L, Xia M, Zhao L, Yang Y, Shi J, Abliz Z. 2004. Multi-stage mass spectrometry of furostanol saponins combined with electrospray ionization in positive and negative ion modes. Rapid Commun Mass Spectrom. 18:235–238.
17. Lorenzati B, Zucco C, Miglietta S, Lamberti F, Bruno G. 2010. Oral hypoglycemic drugs: pathophysiological basis of their mechanism of action oral hypoglycemic drugs: pathophysiological basis of their mechanism of action. Pharmaceuticals (Basel). 3:3005–3020.
18. Monnier L, Lapinski H, Colette C. 2003. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 26:881–885.
19. Proestos C, Kapsokefalou M, Komaitis M. 2008. Analysis of naturally occurring phenolic compounds in aromatic plants by RP-HPLC and GC-MS after silylation. J Food Quality. 31:402–414.
20. Roden M. 2005. Muscle triglycerides and mitochondrial function: possible mechanisms for the development of type 2 diabetes. Int J Obes Relat Metab Disord. 29:111–115.
21. Satterfield M, Brodbelt JS. 2001. Structural characterization of flavonoid glycosides by collisionally activated dissociation of metal complexes. J Am Soc Mass Spectrom. 12:537–549.
22. Schulz KF, Altman DG, Moher D. 2010. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 63:834–840.
23. Sviridov D, Nestel P. 2002. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis. 161:245–254.
24. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, et al. 2009. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 339:b4731
25. World Health Organization. 2000. Preventing and managing the global epidemic. Report of a WHO Consultation. In: WHO Technical Report Series 894: World Health Organization, Geneva.
26. World Health Organisation. 2016. Global report on diabetes: World Health Organization, Geneva.
27. Zanutto FV, Boldrin PK, Varanda EA, Fernandes de Souza S, Sano PT, Vilegas W, Campaner dos Santos L. 2012. Characterization of flavonoids and naphthopyranones in methanol extracts of Paepalanthus chiquitensis Herzog by HPLC-ESI-IT-MSn and their mutagenic activity. Molecules. 18:244–262.